Sanofi S.A., FR0000120578

Sanofi reports 44-week duvakitug data while Sanofi stock costs EUR 74.93

Published on 10/27/2026 at 11:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The 44-week study included 130 patients and showed 58 percent remission at 900 mg. Sanofi stock costs EUR 74.93 on October 27, 2026.

Evidence before October results

Sanofi and Teva reported 44-week duvakitug results on October 20, 2026.
The study included 130 patients, with 58 percent clinical remission at the 900 mg dose.
Sanofi stock traded at EUR 74.93 at 11:02 a.m. CEST at Lang & Schwarz on October 27, 2026.
Sanofi will publish third-quarter 2026 results on October 30, 2026.

Sanofi S.A., FR0000120578, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) traded at EUR 74.93 at Lang & Schwarz on October 27, 2026 at 11:02 a.m. CEST. The pharmaceutical company and Teva reported 44-week duvakitug data on October 20, 2026, giving the pipeline a fresh clinical milestone ahead of Sanofi's third-quarter results.

Three events shape the pipeline

On October 6, 2026, Sanofi announced that third-quarter 2026 results would be published on October 30, 2026. The company's investor-relations page also listed an October 19, 2026 update on a new insulin manufacturing facility in Germany, adding a manufacturing investment angle to the pipeline narrative.

The current event came on October 20, 2026. According to Sanofi, the RELIEVE UCCD phase 2b extension study showed sustained duvakitug outcomes through 44 weeks in ulcerative colitis and Crohn's disease.

What does 44 weeks mean for Sanofi?

The data provide a quantified test of durability, not a regulatory approval. The study included 130 patients, and clinical remission in ulcerative colitis reached 47 percent with the 450 mg dose and 58 percent with the 900 mg dose at Week 44. Clinical response reached 82 percent and 87 percent, respectively, while endoscopic improvement reached 59 percent and 63 percent, according to Teva. The medicine remains investigational, so the next development hurdle is evidence from the ongoing phase 3 program.

Dates investors can measure

Sanofi's investor-relations calendar lists third-quarter 2026 results for October 30, 2026, followed by the Jefferies Global Healthcare Conference in London on November 17, 2026. The results date is the nearer catalyst because management will present the quarter and answer questions from the financial community.

Sanofi is listed on Euronext Paris under SAN and also trades on Nasdaq under SNY, according to the October 20 company release. Its 2025 fiscal-year revenue was EUR 46.7 billion and net income attributable to common shareholders was EUR 7.8 billion, while 2024 revenue was EUR 44.3 billion and net income was EUR 5.6 billion.

Stock price before results

The October 27 quotation gives investors a dated euro reference ahead of the results. The clinical data add a measurable pipeline factor, while the October 30 reporting date will provide the next broader test of sales, earnings and outlook.

Sanofi stock was trading at EUR 74.93 at Lang & Schwarz on October 27, 2026 at 11:02 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.